Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Revenue forecast
View:
Post by lscfa on Feb 17, 2024 12:42pm

Revenue forecast

Per slide 21


 

2025

Units sold

Revenue

Qtr revenue

January

1,550

387,500

 

February

1,938

484,375

 

March

2,422

605,469

1,477,344

April

3,027

756,836

 

May

3,784

946,045

 

June

4,730

1,182,556

2,885,437

July

5,913

1,478,195

 

August

7,391

1,847,744

 

September

9,239

2,309,680

5,635,619

October

11,548

2,887,100

 

November

14,435

3,608,875

 

December

18,044

4,511,094

11,007,069

 

84,022

21,005,469

 

Comment by tylerreddick on Feb 17, 2024 12:55pm
Extrapolate that to 100,000 units/month, which should be easily attainable once word gets out. That is serious money.
Comment by tylerreddick on Feb 17, 2024 1:03pm
December's number is $55 million of annualised revenue, or about 17 cents/share FD. Margins should be very good, one would think at least 35%, which would give us earnings of 6 cents/share. A biotech with growing earnings and more potential products could easliy demand a PE ratio of 30 (or more). Can anyone get their head around a $2 share price? That would get some attention.
Comment by bealert on Feb 17, 2024 5:27pm
The extrapolation sounds great.  I think waiting until 1st quarter of 25 is a bit slow.  They must be able to get at least some advance product out there before that.  Why should we have to wait another year after we have already waited over 16 years for this thing to get some wheels? About the bonus shares that Howhee received:  Are these free to him for backing the loan ...more  
Comment by lscfa on Feb 17, 2024 5:51pm
Geraldine noted in interview that clinical trials of formulations containing the active ingredient are required even if clinical trials of active ingredient have been done. 2nd half of 2024 is target for formulation trials. 
Comment by LakeOromocto on Feb 17, 2024 8:34pm
You call them and offer to loan the funds. How many PP have you participated in? Don't bite the hand that keeps the lights on!
Comment by sakinny3 on Feb 18, 2024 11:19am
So they are planning to sell this for 250$ a go? That's not exactly mass market price
Comment by lscfa on Feb 18, 2024 1:36pm
$250 is likely the price for a regimen like other companies do. e.g. 21 day intensive treatment, 50ml stronger face cream, 50ml milder face cream.
Comment by tylerreddick on Feb 18, 2024 3:36pm
It looks like that price is probably for the trays with a the 21 little tubes of treatment, thus the 21-day regimen https://twitter.com/SironaBiochem/status/1752228505402667105
Comment by lscfa on Feb 18, 2024 3:58pm
So $250 is likely for the serum (21 days), stronger face cream (4 to 6 wks) and milder face cream (4 to 6 weeks). After that, repeat sales of the milder face cream to maintain => $70 every 4 to 6 weeks?
Comment by lscfa on Feb 18, 2024 4:07pm
  2025 Starter Units sold Revenue Cumulative customers Lag Maintenance sales @$70/mo Total sales January 1,550 387,500 1,550     February ...more  
Comment by sakinny3 on Feb 19, 2024 1:50am
Can you tell me where all this estimated revenue data is coming from? I can't find it on the company websites.  Thanks
Comment by lscfa on Feb 19, 2024 2:07pm
Alternative view. The $21M revenue includes starter kits (serum, 0.5% cream, 0.2% cream) and reorders for maintenance (0.2% cream)   2025 Starter Kit 70% Reorder Starter rev @ $300 Reorder rev @ $100/mo Total Revenue January 1,550  ...more  
Comment by biorun on Feb 19, 2024 3:06pm
Good table. I would think an analysis which shows a 10 year proforma, discounted in present value terms would give an interesting NPV per share number. Some numbers could be a 13x to 20x PE mumtiple, and 12% discount rate to reflect the corporate loan rate.
Comment by gr0und1ng on Feb 19, 2024 4:43pm
Now halve the numbers or move the decimal point one place forward and we are in a real possibility.   Not that anyone will be disappointed if the numbers are not reached ;-)
Comment by sakinny3 on Feb 20, 2024 1:11am
Hi Iscfa, on your reorder data, have you compounded as people will continue to reorder? Data seems to just account for 1 reorder?
Comment by lscfa on Feb 20, 2024 2:26am
Sakinny, good catch. If the table is corrected for recurring monthly reorders the starter kit would cost $400 and the reorder $125/mo.  This seem high. Sirona's slide 21 does not add up anyway. If you eyeball the bars you would get 40,000 units sold vs 84,000 noted, and revenue bars add up to $16M vs $21M noted. We need more clarity.   2025 ...more  
Comment by forhandlaren on Feb 20, 2024 3:21am
Let's take a look on the anticipated product line and the revenue forecast. I'm not so sure that the revenue forecast includes Maintenance revenue at all, only the Concentrate Ampoules or possibly bundled with a box of Anti-aging cream. Concentrate Ampoules (2025) 21 day program Anti-aging Creams (2025) Maintenance with strong / mild concentration Hand Cream (2026) Anticellulite ...more  
Comment by forhandlaren on Feb 19, 2024 2:58am
The initial lauch is planned for USA and Canada Q1 2025. The products are expected to be launched in Europe, Guld states and Australia New Zealand starting Q4 2025. China, Japan and South Korea in 2026. A two year rollout. A forecast is a forecast. I took the liberty to extrapolate the numbers by Iscfa into year two and ended up with stellar numbers - not counting Maintencance sales. In ...more  
Comment by tylerreddick on Feb 19, 2024 8:38am
" Total margin is 90 percent. " Well, you just destroyed the little credibility you had.
Comment by lscfa on Feb 19, 2024 11:52am
90% margin is gross margin. Marketing costs will be a large expense impacting operating margin and net profit margin.
Comment by tylerreddick on Feb 19, 2024 12:05pm
Thanks for confirming what I posted.
Comment by forhandlaren on Feb 19, 2024 9:11am
@tylerrreddick I accidentally noticed your comment since I wasn't logged in. The 90 percent has been stated by management. For the record. I don't care about your perception of my posts, please feel free to ignore me. I'll log in now so I won't be able to respond you from now on.
Comment by tylerreddick on Feb 19, 2024 9:54am
" I accidentally noticed your comment since I wasn't logged in " Even more credibility erased. 
Comment by sakinny3 on Feb 19, 2024 9:37am
Is it correct to say that the presentation all the forecast data is taken from has not formally been released by the company?
Comment by JL202101 on Feb 19, 2024 11:31am
https://glycoprotemim.com At the bottom of the web page, there is a Disclaimer. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical ...more  
Comment by lscfa on Feb 19, 2024 10:36am
Not sure how to project sales beyond 2025. Sirona is adding a hand cream in 2026....   GlycoProteMim™ Hand Cream Our age-defying hand cream, enriched with the power of GlycoProteMim, is specially formulated to target and reduce wrinkles on the back of the hands. This luxurious cream also moisturizes, hydrates, and provides overall skin rejuvenation.  ...more  
Comment by lscfa on Feb 19, 2024 5:47pm
I can envision GPM being licensed to someone for sales in Asia, possibly after doing further studies on different skins types.  The study done in Paris was on only 20 women. Were they all caucasians?
Comment by forhandlaren on Feb 20, 2024 1:51am
Geraldine has mentioned the idea of creating specialized compounds for different skin types. It is an idea in general put through over the years, not sure if needed for anti-aging.  The roll-out in Asia is planned as the third wave, could be because of skin type adaption or just plain marketing logistics. South America, India, Indonesia and so on seems to be open for third party deals. That ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities